LVTX insider transaction filings
LAVA Therapeutics NV — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-11-17. Screen LVTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-11-17 | 4 | Oliger Christy J. — Director | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Wadlinger Mary E. — Director | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Backstrom Jay T. — Director | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Dhingra Kapil — Director | Disposition to issuer (D): 30,000 · Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Noble James — Director | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Powell Fred M — Chief Financial Officer | Disposition to issuer (D): 65,000 · Disposition to issuer (D): 124,700 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Kiener Peter A — Director | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | WILSON KAREN J — Director | Disposition to issuer (D): 10,000 · Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | HURLY STEPHEN A — Chief Executive Officer, Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 335,100 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | Cooperatieve Gilde Healthcare IV U.A. — 10% owner Gilde Healthcare Holding B.V. — 10% owner | Sale (S): 690,239 @ $1.49 · Sale (S): 1,181,131 @ $1.47 · Sale (S): 1,000,000 @ $1.46 | EDGAR |
| 2025-10-15 | 4 | Cooperatieve Gilde Healthcare IV U.A. — 10% owner Gilde Healthcare Holding B.V. — 10% owner | Sale (S): 47,686 @ $1.54 · Sale (S): 227,341 @ $1.51 · Sale (S): 200,000 @ $1.51 | EDGAR |
| 2025-10-10 | 4 | Cooperatieve Gilde Healthcare IV U.A. — 10% owner Gilde Healthcare Holding B.V. — 10% owner | Sale (S): 28,954 @ $1.57 · Sale (S): 48,169 @ $1.56 · Sale (S): 49,869 @ $1.55 | EDGAR |
| 2025-09-23 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage I, L.P. — 10% owner Versant Vantage I GP, L.P. — 10% owner Versant Vantage I GP-GP, LLC — 10% owner | Sale (S): 2,370,533 @ $1.40 · Sale (S): 532,870 @ $1.40 | EDGAR |
| 2025-09-18 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage I, L.P. — 10% owner Versant Vantage I GP, L.P. — 10% owner Versant Vantage I GP-GP, LLC — 10% owner | Sale (S): 307,707 @ $1.53 · Sale (S): 192,293 @ $1.53 · Sale (S): 362,806 @ $1.49 · Sale (S): 226,726 @ $1.49 · Sale (S): 366,111 @ $1.44 · Sale (S): 228,791 @ $1.44 | EDGAR |
| 2025-02-18 | 4 | Oliger Christy J. — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Wadlinger Mary E. — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Backstrom Jay T. — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Morris Charles Q — Chief Medical Officer | Grant/award (A): 130,850 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Dhingra Kapil — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Noble James — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Powell Fred M — Chief Financial Officer | Grant/award (A): 124,700 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Kiener Peter A — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | WILSON KAREN J — Director | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | HURLY STEPHEN A — Chief Executive Officer, Director | Grant/award (A): 335,100 (derivative) @ $0 | EDGAR |
Recent 8-K events — LAVA Therapeutics NV
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-11-21 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-07 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-10-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-23 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LVTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →